Production of clinical-grade recombinant adeno-associated virus vectors
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 13 (5), 418-423
- https://doi.org/10.1016/s0958-1669(02)00369-5
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- [23] Recombinant adeno-associated viral vector production using stable packaging and producer cell linesMethods in Enzymology, 2002
- Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genomeThe Journal of Gene Medicine, 2000
- Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2Gene Therapy, 1999
- Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirusGene Therapy, 1999
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- New developments in the generation of Ad-free, high-titer rAAV gene therapy vectorsNature Medicine, 1997
- Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.Proceedings of the National Academy of Sciences, 1994
- Acquisition of the human adeno-associated virus type-2 rep gene by human herpesvirus type-6Nature, 1991
- The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activityCell, 1990
- EPIDEMIOLOGY OF ADENOVIRUS-ASSOCIATED VIRUS INFECTION IN A NURSERY POPULATION1American Journal of Epidemiology, 1968